Treatment of advanced, high-grade soft-tissue @entity242 with @entity1260 and continuous-infusion XXXX .

@entity1 @entity137 @entity1261 @entity242 @entity1418 @entity882 @entity2879 @entity1822 @entity1431 @entity3 @entity1260 @entity221
A total of 33 @entity1 (median age, 44 years) with high-grade, adult soft-tissue @entity242 were treated with @entity2879 given at 600 mg/m2 in a 72-h continuous infusion and @entity1260 given at 1500 mg/m2 per day for 3 days every 3 weeks. Dose escalation/reduction was protocolled depending on the level of hematological @entity137 observed in the preceding course. Overall, 90% of @entity1 had @entity3 , and the most common histologies were @entity1418 and @entity1822 . A median of 5 (range, 1-9) courses were given. Of 30 @entity1 who were evaluable for response, 12 (40%) obtained a partial remission, and the median time to progression was 8 (range, 4-13) months. Grade 3-4 @entity1431 and @entity882 were seen after 89% and 8% of the courses, respectively; @entity221 was seen in half of the @entity1 (15% of courses); and 32% of courses had to be postponed by 7 days or more due to myelosuppression. Dose reduction to below the standard had to be performed in 46% of courses, and dose escalation was achieved in only 13%. The reduced @entity137 seen after the addition of @entity1261 ( @entity1261 ) in five @entity1 indicates that growth-factor support may enhance the dose intensity of the regimen. The results indicate significant activity for this regimen in adult soft-tissue @entity242 , which may in part be a result of the escalated dose and prolonged mode of administration of the phase-specific agent @entity2879 . As a result of this pilot series, a phase II study with @entity1260 , @entity2879 , and @entity1261 in advanced adult soft-tissue @entity242 has been initiated by the Scandinavian Sarcoma Group.
